Overview
Register
Day 1
Day 2
Speaker Biographies
20 for 20 Special Offer  

PDF Download 
Hotel & Travel 
Sponsor 
Press Pass 
Request Brochure 

Corporate Sponsor

Archimedes


Corporate Support Sponsor

ERT




Lead Sponsoring Publications

Bio-IT-Word_logo

eCliniqua Logo

Science Magazine – AAAS

The Scientist


Sponsoring Publications


Center Watch Classic

Insight Pharma Reports

PharmaVoice


Media Partner


Web Partners

CanBiotech logo
Pharmaphorum

Pharm Cast


CHI's BioPharma Strategy Series' Inaugural Phase III Clinical Trials Conference - Day 2


Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!



Tuesday, March 13, 2012


7:30 am Breakfast Presentation (Sponsorship Opportunity Available, please contact Carol Dinerstein: dinerstein@healthtech.com, 781-972-5471) or Morning Coffee 

8:00 Roundtable Discussions: Join your fellow delegates  for a morning coffee and lively discussion of current topics related to Phase III. Choose a table and join the discussion.

  • Table 1: Impact of Comparative Effectiveness Research in Phase III
  • Table 2: Quantitative Decision Making for Improved Drug Development
  • Table 3: The Challenge of Personalized Medicine in Phase III Trials

 

PHASE II TO PHASE III TRANSITION:
TRIAL DESIGNS AND STRATEGIES

8:45 FEATURED SPEAKER:

Moving to Phase III in an Orphan Disease: Lessons from the Vertex Cystic Fibrosis Program

Eric Olson, Ph.D., Vice President, Cystic Fibrosis Franchise Lead, Vertex Pharmaceuticals, Inc.


9:30 FEATURED SPEAKER:

Phase III Challenges in Neurology Drug Development

Michael Krams, M.D., Vice President, Research & Development; Head, Neurology Franchise, Johnson & Johnson


10:15 Speed Networking 

An exciting way to meet your fellow conference attendees and speakers! Bring extra business cards to exchange. Each "mini networking 1-on-1" will be 3 minutes long.

10:45 Networking Coffee Break in the Exhibit Hall


» 11:15 Session PRESENTATION:

Evidentiary Standards for Surrogate Endpoints, Genetic Testing & CDx

Stephen WilliamsStephen A. Williams, M.D., Ph.D., CMO, SomaLogic, Inc.

How can we explain, understand and manage the perceived differences in evidentiary standards viewed as reasonable by Pharma and regulatory authorities? This talk will use examples such as suicidality, cardiovascular risk and K-ras, while providing evidence from recent case studies and standards set by the FDA.

11:45 Lessons Learned from a Phase 2 Systemic Lupus Erythematosus (SLE) Study with Belimumab Enabled Design of Phase 3 BLISS Trials

William W. Freimuth, M.D., Ph.D., Vice-President of Clinical Research Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences, Inc.

Belimumab is a human monoclonal antibody which inhibits B-Lymphocyte Stimulator (BLyS) and has been developed as a novel therapeutic for patients with SLE.  BLyS is responsible for the survival and differentiation of B-cells to antibody producing plasma cells. Post-hoc analysis of a belimumab dose ranging phase 2 study in active SLE patients receiving standard therapy identified an autoantibody subpopulation responsive to belimumab.  Lessons learned led to design of phase 3 BLISS trials and creation of a novel primary endpoint called the SLE responder Index (SRI).

 

CASE STUDIES & LESSONS LEARNED

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own


1:30 FEATURED SPEAKER:

Talk Title to be Announced

Charles Knirsch, M.D., M.P.H., Vice President, Clinical Affairs Head, Specialty Therapeutics, Pfizer, Inc.


2:15 The Case for Early Failure Studies

Doina Roman, M.D., Senior Medical Director, Translational Medicine Sciences, Takeda Global Research & Development, Inc.

The talk will focus on the practical use of translational medicine/biomarkers in drug development. Compound failure in Phase III is costly, but lessons can be learned from these studies and applied to drugs in development as early as pre-clinical and early clinical stages by utilizing translational medicine principles. Identifying mistakes, patterns, and decision-making criteria can be a successful tool in both establishing a Phase 3 implementation program and a successful NDA submission.

2:45 EXPERT PANEL:

What Does Your Ideal Phase III Package Look Like?

Join experts from the clinical community in discussing what the ideal Phase III-ready package looks like. What proof-of-concept data and confidence will you require and would you include simulation and modeling data? Explore both business and scientific decision making requirements.


3:30 Phase III Success: the CRO Perspective

Judith Quinlan, M.Sc.,  Senior Vice President, Trial Design Implementation, Aptiv Solutions’ Innovation Center

4:00 Biomarkers in Phase III Clinical Trials: Potential Applications and Caveats

Abdel Halim, Pharm.D., Ph.D., DABCC-CC, DABCC-TOX, DABCC-MD, FACB, Director, Clinical Biomarkers, Daiichi Sankyo Pharma Development

4:30 End of Conference




By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs